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To identify systemic risk factors for sickle cell maculopathy, and to analyze the microstruc-
ture of the macula of Sickle Cell Disease (SCD) patients by using automated segmentation
of individual retinal layers.
Methods
Thirty consecutive patients with SCD and 30 matched controls underwent spectral-domain
optical coherence tomography (SD-OCT) and automated thickness measurement for each
retinal layer; thicknesses for SCD patients were then compared to normal controls. Demo-
graphic data, systemic data, and lab results were collected for each SCD patient; multivari-
ate logistic regression analysis was used to identify potential risk factors for sickle cell
maculopathy.
Results
Ongoing chelation treatment (p = 0.0187) was the most predictive factor for the presence of
sickle cell maculopathy; the odds were 94.2% lower when chelation was present. HbF level
tended to influence sickle cell maculopathy (p = 0.0775); the odds decreased by 12.9%
when HbF increased by 1%. Sickle cell maculopathy was detected in 43% of SCD patients
as patchy areas of retinal thinning on SD-OCT thickness map, mostly located temporally to
the macula, especially in eyes with more advanced forms of sickle cell retinopathy (p =
0.003). In comparison to controls, SCD patients had a subtle thinning of the overall macula
and temporal retina compared to controls (most p<0.0001), involving inner and outer retinal
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layers. Thickening of the retinal pigment epithelium was also detected in SCD eyes
(p<0.0001).
Conclusions
Chronic chelation therapy and, potentially, high levels of HbF are possible protective factors
for the presence of sickle cell maculopathy, especially for patients with more advanced
forms of sickle cell retinopathy. A subtle thinning of the overall macula occurs in SCD
patients and involves multiple retinal layers, suggesting that ischemic vasculopathy may
happen in both superficial and deep capillary plexi. Thinning of the outer retinal layers sug-
gests that an ischemic insult of the choriocapillaris may also occur in SCD patients.
Introduction
Approximately 60,000 people in the USA and 10,000 in the United Kingdom suffer from Sickle
Cell Disease (SCD), making it one of the most common genetic disorders.[1] In SCD, erythro-
cytes deform into a sickle shape, resulting in vaso-occlusive complications in multiple organs.
Ocular complications are commonly observed in SCD, and involve the retina in particular.
Proliferative sickle cell retinopathy (PSR) is the major sight-threatening complication, most
frequently observed in hemoglobin SC disease.[1] Goldberg in the early 70’s extensively stud-
ied PSR, and described 5 stages characterized by peripheral retinal ischemia, peripheral neo-
vascularization, intravitreal hemorrhage, and tractional or mixed retinal detachment.[2] This
peculiar retinopathy has been of particular interest in several studies as it is considered a
model of purely ischemic retinopathy without an exudative component.[3]-[4] Another
emerging complication is ‘sickle cell maculopathy’, which is a localized macular thinning sec-
ondary to ischemia. Sickle cell maculopathy is a subtle disease which is not always clinically
apparent on indirect ophthalmoscopy; instead, it is more easily detectable using spectral
domain optical coherence tomography (SD-OCT) and OCT angiography (OCT-A). Early his-
topathologic studies demonstrated loss of the inner retinal layers in SCD patients[5], while iso-
lated studies using SD-OCT have shown inner or outer macular thinning without clinical
evidence of nonperfusion on fluorescein angiography (FA)[6–8], as well as patchy areas of
severe retinal thinning in the temporal macula.[8, 9] The exact etiology of macular thinning in
the absence of clinically apparent nonperfusion still remains unclear. However, recent OCT-A
evidence has suggested that nonperfusion of the retinal capillary plexi may be responsible for
the areas of macular thinning seen in SCD patients that was seen on SD-OCT.[9–12] As Mar-
tin et al have demonstrated[13], temporal macular atrophy in sickle cell disease may have
direct consequences on visual function even when the visual acuity is preserved. Indeed, areas
of retinal thinning in asymptomatic patients were found to match with paracentral scotomas
on automated perimetry. Therefore, irreversible visual loss can occur either secondary to PSR
or sickle cell maculopathy, and identifying patients at risk for SCD ocular complications can
be crucial to limit drastic consequences for patients’ vision and quality of life. Previous investi-
gators have demonstrated that PSR severity is potentially associated with SC genotype, lower
fetal hemoglobin (HbF), and higher hemoglobin levels.[14] It has also been reported that cir-
culating PEDF and low sICAM-1 are associated with sickle cell retinopathy.[4] On the con-
trary, given that sickle cell maculopathy has been studied only recently, demographic or
systemic risk factors for the occurrence of irreversible severe retinal thinning in sickle cell
maculopathy have not been evaluated yet.
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The primary purpose of the present study was to identify the potential role of demographic
and systemic factors not yet investigated on the occurrence of sickle cell maculopathy, in order
to provide useful information to clinicians who are managing SCD patients from the hemato-
logical and ophthalmological standpoint. The secondary purpose was to analyze the micro-
structure of the macula of SCD patients by evaluating the thickness of each individual retinal
layer using an automated software for retinal segmentation; such evaluation may bring further
evidence and eventually provide a more comprehensive explanation of the occurrence and
implications of sickle cell maculopathy.
Materials and methods
Patients
The research adhered to the tenets of the Declaration of Helsinki, and approval by the investi-
gational review board of the Fondazione IRCCS CàGranda, Ospedale Maggiore Policlinico,
was obtained. A signed written informed consent form was obtained from each participant
(SCD patients and controls). This prospective, cross-sectional, case-control study was per-
formed at the University of Milan, Ospedale Maggiore Policlinico of Milan. Patients with SCD
were recruited in a tertiary referral center in Milan (Department of Internal Medicine, Rare
Diseases Center, Fondazione IRCCS Ca’ Granda-Ospedale Maggiore Policlinico, Italy) and
were evaluated consecutively at the Department of Ophthalmology of the same institution
between March 2014 and October 2015. Only patients with age 18 or above and with electro-
phoretic confirmation of SCD (HbSS, HbSC, or HbS/β˚) were recruited. Ophthalmic examina-
tions were conducted after explanation of the procedures and receipt of written informed
consent, and included best corrected visual acuity (BCVA) measurement, slit-lamp evaluation,
indirect ophthalmoscopy, SD-OCT and FA. All examinations for an individual study partici-
pant were performed on the same day. If signs of retinal abnormalities not related to SCD
were detected (e.g., inherited retinopathy, age-related macular degeneration, presence of epir-
etinal membrane, or diabetic retinopathy), patients were excluded from the study. In addition,
we excluded patients with high myopia (> -6 diopters), with media opacities not allowing
good-quality ocular imaging, and patients previously treated with panretinal photocoagulation
for PSR. Data from both eyes of each participant were used for the analyses, unless there were
ocular abnormalities that could affect visual function in either eye. An age and sex-matched
control group of healthy patients was also recruited, and underwent the same ocular proce-
dures, except for FA.
Ocular imaging
1) Fluorescein angiography.
• Conventional FA was performed with series of early frames both with standard foveal fixa-
tion and temporal fixation (12.5 degrees temporally to the fovea), acquired with the
30-degree standard lens. Retinal periphery was studied evaluating the 9 standard fields (tem-
poral-superior, superior, nasal-superior, nasal, inferior nasal, inferior, temporal-inferior,
temporal and posterior pole) with the 55-degree lens or with Staurenghi lens (Staurenghi
230 SLO Retina Lens; Ocular Instruments Inc., Bellevue, Washington) at the physician’s
discretion.
• Evaluation of macular vascular abnormalities and determination of the stage of sickle cell
retinopathy were based on FA, and was performed by two trained independent physicians.
In case of disagreement, a third physician was consulted to achieve an acceptable result. The
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diagnosis of macular vascular abnormalities included the presence of microaneurysms,
ischemic areas, anastomosis, and/or hairpin-shaped venous loops.
• PSR features were graded according to the Goldberg classification[2] as follows: stage 0, fully
vascularized peripheral retina; stage I, peripheral retinal ischemia; stage II, peripheral arte-
riovenous anastomosis; stage III, peripheral neovascularization; stage IV, intravitreous hem-
orrhage; stage V, retinal detachment. In case a patient presented with previously performed
focal laser treatment for peripheral neovascularization, patients were classified as stage III.
The severity of sickle cell retinopathy was obtained by classifying eyes into three groups
according to the presence of proliferative changes: no retinopathy (stage 0), non proliferative
retinopathy (i.e., Goldberg stage I and II), and proliferative retinopathy (i.e., Goldberg stage
III, IV and V).
2) Optical coherence tomography.
• OCT was carried out using the Spectralis SD-OCT (Heidelberg Engineering, Heidelberg,
Germany) for all patients; the standard scanning protocol included 31 high-resolution B-
scans, and each scan was approximately 9 mm in length and spaced 240 microns apart. All
31 B-scans were acquired in a continuous, automated sequence and covered a 30˚ x 25˚ area.
A minimum of 20 frames were averaged automatically and used to obtain a good quality
image. The central fixation target was used to center the raster scan to the fovea while the
12.5-degree temporal fixation target was used to center the scan temporally to the fovea. The
same protocol was repeated using the Enhanced Depth Imaging (EDI) mode to better study
the choroid. (Fig 1).
• Color-coded retinal thickness maps centered on the fovea and temporally to the fovea were
automatically generated by the built-in software of the device after applying the ETDRS grid
(Fig 1). Measurements of retinal thickness and choroidal volume were recorded. The
ETDRS grid divides the macula into 3 concentric rings (center, inner, and outer), with the
inner ring measuring 1 to 3 mm and the outer ring measuring 3 to 6 mm of diameter (refer-
ring to a ring with a diameter of 1 mm). The grid further divides inner and outer rings into 4
quadrants (superior, inferior, temporal, and nasal). Thickness data from the nasal quadrant
and central ring of the temporally-centered grid were not collected because of overlapping
with the temporal quadrant of the fovea-centered grid (Fig 1).
• To study the choroid, one trained physician manually performed the choroidal segmentation
using a previously described well-reproducible method[15], and then the software automati-
cally provided the choroidal volume within the ETDRS grid (Fig 1).
• Individual retinal layers were automatically segmented using the built-in segmentation soft-
ware of the Heidelberg Eye Explorer software, after which a trained ophthalmologist (GB)
reviewed the results and occasionally corrected the segmentation lines where necessary. The
segmentation software then provided thickness maps and measurements from each retinal
layer in the ETDRS grid as follows; retinal nerve fiber layer (RNFL), ganglion cell layer
(GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL),
outer nuclear layer (ONL), photoreceptor layer (PR), and retinal pigment epithelium (RPE)
thicknesses (Fig 1). A previous study has demonstrated that thickness estimates using the
Heidelberg Eye Explorer software were highly repeatable for all retinal layers, except the
OPL.[16]
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• SCD eyes were divided into two groups based on the presence of sickle cell maculopathy,
identified as patchy areas of severe retinal thinning on OCT (i.e., blue areas of markedly
decreased thickness on retinal thickness color-coded map) (Fig 2).
Data collection
Clinical data were collected from the patient’s hematological charts, and included demograph-
ics (age, gender, ethnicity), ocular history, medical history (SCD type, transfusion treatment,
Fig 1. Optical coherence tomography imaging protocol and analysis, for both foveal-centered and temporally
centered scans. (Left column) Color-coded retinal thickness maps were generated by the built-in software of the
device, which then automatically applied the ETDRS grid after scanning eyes using 31 high-resolution B-scans. The
nasal quadrant and the central ring of the temporally-centered scan were systematically not measured because
overlapping with the temporal quadrant of the foveal-centered scan. (Right column) The segmentation software of the
SD-OCT device automatically detected each retinal layer, including retinal nerve fiber layer, ganglion cell layer, inner
plexiform layer, inner nuclear layer, outer plexiform layer, outer nuclear layer, photoreceptor layer, and retinal
pigment epithelium. Segmentation of the choroid was performed manually.
https://doi.org/10.1371/journal.pone.0193582.g001
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Fig 2. Example of sickle cell maculopathy. (First and third rows) Patchy areas of markedly reduced retinal thickness
are visible as blue areas on retinal thickness maps. (Second and fourth row) Automatic segmentation of the B-scans
passing through thinned areas demonstrates thinning of multiple individual retinal layers (white arrows).
https://doi.org/10.1371/journal.pone.0193582.g002
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iron-chelation and hydroxyurea therapy, spleen status, previous ischemic events), hematology
values (fetal hemoglobin (HbF), sickle hemoglobin (HbS), reticulocytes, leucocytes, neutro-
phils, hemoglobin, hematocrit, lactate dehydrogenase (LDH), total and indirect bilirubin,
aspartate aminotransferase (AST), alanine aminotransferase (ALT), ferritin, transferrin satura-
tion, mean corpuscular volume (MCV), platelets, creatinine, urea, uric acid). Labs value were
recorded from the last on-site consultation, that was performed the same month of the oph-
thalmological evaluation.
Statistical methods
Sickle Cell Disease patients were evaluated for potential risk factors which may influence sickle
cell maculopathy (occurring in one or both eyes). Univariate logistic regression was used to
model the proportion of patients with sickle cell maculopathy for multiple demographic and
systemic factors. A multivariate logistic regression model was then fit incorporating factors
from the univariate analyses with p0.10. To identify risk factors that independently contrib-
ute to sickle cell maculopathy, a stepwise selection procedure was used required a p-value
0.10 for a variable to enter the model and a p-value0.10 to remain in the model.
Sickle Cell Disease patients and matched controls were used to compare retinal layers and
choroidal thicknesses located central and temporal to the fovea. A univariate analysis of vari-
ance model was fit to each retinal layer variable incorporating factors for pair (includes 30
SCD/control matched pairs), eye (OD, OS) and group (SCD, control). These same retinal layer
thickness variables were fit, using SCD patients only, to compare patients with sickle cell
maculopathy in one or both eyes versus patients without sickle cell maculopathy. A univariate
analysis of variance model was fit to each retinal layer variable incorporating factors for
patients (30 SCD patients), eye (OD, OS) and sickle cell maculopathy group.
Statistical analyses were performed using SAS statistical software version 9.2 (SAS Inc,
Cary, NC). ANOVAmodels were fit using PROC GLM and logistic regression models fit
using PROC LOGISTIC.
Results
Fifty-nine eyes of 30 consecutive patients with SCD were included in the study. There were 18
women and 12 men. Eighteen patients were Caucasian, 7 African-American, and 5 with His-
panic origin. The mean age of the patients was 38.7 years (range, 22–70 years) and included 9
HbSS (30%), 17 HbS/β˚ (56.5%), and 4 HbSC (13.5%) (Table 1). Data on both eyes were col-
lected and analyzed, except for 1 eye that was excluded due to anisometropic amblyopia. Best
correct visual acuity ranged from 20/25 to 20/20. Due to known allergies, FA was not per-
formed to 2 patients. Across 28 patients who underwent FA, 16 eyes (29%) showed no sign of
retinopathy, 23 eyes (42%) showed nonproliferative retinopathy, and 16 eyes (29%) showed
proliferative retinopathy. Twelve out of 59 eyes (20%) underwent limited focal laser treatment.
Twenty-one out of 55 eyes (38%) showed macular vascular irregularities on FA.
Thirteen out of 30 SCD patients (43%), for a total of 19 out of 59 eyes (32%), were noted to
have sickle cell maculopathy, detected as patchy areas of severe thinning on SD-OCT thickness
maps (Fig 2). The patchy areas of retinal thinning were located temporally to the macula in 19
out of 19 eyes (100%), while 13 out of 19 eyes (68.5%) also showed an involvement of the tem-
poral quadrant of the macula itself. Univariate analysis (Table 2) revealed a significant correla-
tion between the presence of sickle cell maculopathy and transfusion therapy (p = 0.0123),
chelation treatment (p = 0.0076), HbF (p = 0.0278), neutrophils (p = 0.0364), acid uric
(p = 0.0462), ferritin (p = 0.0346), and transferrin saturation (p = 0.0038). However, the most
predictive factors for the occurrence of sickle cell maculopathy as assessed after multivariate
Sickle cell maculopathy: Identification of systemic risk factors, and microstructural analysis of the macula
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regression analysis was chronic chelation treatment (p = 0.0187). HbF level also tended to pre-
dict occurrence of this diseases (p = 0.0775) (Table 3). More specifically, the odds of sickle cell
maculopathy were 94.2% lower when chelation was present, and the odds decreased by 12.9%
when HbF increased by 1%.
While investigating the relationship between severity of sickle cell retinopathy and the pres-
ence of sickle cell maculopathy, we found that the prevalence of sickle cell maculopathy was
higher in eyes with more severe sickle cell retinopathy; in particular, patchy areas of severe reti-
nal thinning were present in 62.5% (10/16) of the eyes with proliferative retinopathy, 30% (7/
23) of the eyes with nonproliferative retinopathy, and 6% (1/16) of the eyes without retinopa-
thy (p = 0.003). Furthermore, the prevalence of sickle cell maculopathy tended to be greater in
eyes showing macular vascular abnormalities on FA (47%, 10/21) in comparison to eyes with
normal FA (23.5%, 8/34).
Pairwise comparison between SCD patients (with or without sickle cell maculopathy) and
normal controls showed that SCD patients had a generalized thinning of the total retinal thick-
ness, both of the macula and of the temporal retina (see Table 4 for details). In particular, most
quadrants of the central ETDRS grid showed a significant thinning of multiple retinal layers
including GCL, IPL, INL, and ONL (with OPL reduced only inferiorly), while all the quadrants
of the temporal ETDRS grid showed a significant thinning of both the INL and ONL (see
Table 5 for details). Thickening of the RPE was detected in SCD eyes compared to controls in
all quadrants, both centrally and temporally (see Table 5 for details). An example of thickness
maps and measurements for each retinal layer from a SCD patient of our cohort can be found
in Fig 3. Choroidal volume was similar between SCD eyes and control eyes.
The comparison between SCD eyes with and without sickle cell maculopathy didn’t show
any statistical difference in the thickness of any layer in the central macula. However, tempo-
rally to the macula it was noted a generalized retinal thinning in the superior and temporal
quadrants (see Table 6 for details). More specifically, GCL, IPL, INL, OPL and ONL had a sig-
nificant thinning in the temporal quadrant (Table 7) with INL and OPL thinned also in the
superior and inferior sectors respectively. There was no significant difference in RPE thickness
and choroidal volume measurements, neither centrally or temporally (Table 7).
Table 1. Baseline characteristics of the sickle cells disease population of this study.
Age, years














SD, standard deviation; SCD, sickle cell disease
https://doi.org/10.1371/journal.pone.0193582.t001
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Discussion
Systemic risk factors for the occurrence of sickle cell maculopathy have not been previously
investigated; however, preventing the occurrence of patchy areas of severe retinal thinning is
critical to minimize risk of irreversible visual function loss. Indeed, decreased retinal sensitivity
and macular scotoma were demonstrated in eyes with severe macular thinning.[3, 13, 17] An
Table 2. Univariate analysis for sickle cell maculopathy.
Factors Sickle maculopathy present Sickle maculopathy absent p value
Gender (female) 62% 24% 0.0610
Age (y) 39.8 38.7 0.7568
Ethnicity (white) 46% 71% 0.3891
SCD type
SS 38% 71% 0.2300
SC 38% 24%
Sb 23% 6%
Transfusions (Y) 61% 94% 0.0123
Chelation (Y) 8% 59% 0.0076
Oncocarbide (N) 77% 41% 0.0711
Splenectomy (N) 46% 41% 1.0000
Ischemic events status (N) 62% 53% 0.7273
HbF (%) 5.2 15.0 0.0278
HbS (%) 67.3 56.7 0.1321
Reticulocytes (%) 0.225 0.245 0.6652
Leucocytes (%) 7.3 8.8 0.1105
Neutrophils (%) 3.6 5.1 0.0364
Hemoglobin (g/dL) 9.9 9.6 0.6379
Hematocrit (%) 28.4 27.9 0.7980
LDH (U/L) 328.1 358.5 0.5492
Urea (mg/dL) 26.3 28.9 0.7319
Uric acid (mg/dL) 5.7 4.6 0.0462
Bilirubin-tot (mg/dL) 1.8 2.3 0.1932
Bilirubin-direct (mg/dL) 0.61 0.71 0.2612
AST (U/L) 36.7 42.5 0.6032
ALT (U/L) 26.1 38.4 0.4017
Ferritin (ng/mL) 341.9 1306 0.0346
Transferrin saturation (%) 25.0 48.0 0.0038
MCV (fL/red cell) 73.5 78.5 0.2210
Platelets (GI/L) 288.4 369.5 0.1958
Creatinine (mg/dL) 0.80 0.72 0.6041
SCD, sickle cell disease; LDH, lactate dehydrogenase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; MCV, mean corpuscular volume
https://doi.org/10.1371/journal.pone.0193582.t002
Table 3. Results of the stepwise logistic regression model for sickle cell maculopathy.
Odds Ratio Estimates
Effect Point Estimate 95%Wald
Confidence Limits
Pr> ChiSq
Chelation (N vs Y) 0.058 0.005 0.062 0.0187
HbF 0.871 0.748 1.015 0.0775
https://doi.org/10.1371/journal.pone.0193582.t003
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unreported and striking finding from our analysis, chelation therapy was identified as the
most protective factor against occurrence of sickle cell maculopathy, potentially followed by
HbF levels. The odds of severe retinal thinning was 94.2% lower in case of ongoing chelation
therapy, and the odds of severe retinal thinning decreased by 12.9% when HbF increased by
1%. Sickle cells patients have chronic anemia, which is partially corrected by occasional trans-
fusions. Blood transfusions also decrease the percentage of HbS and reduce hemolysis, there-
fore reduce complications in SCD patients.[18] Indeed, in SCD dense red blood cells
containing polymerized HbS may be responsible for repeated reversible arteriolar occlusions
resulting in areas of retinal non-perfusion.[19] Therefore, chronic hypoxia may explain the
increased risk of retinal thinning in patients not regularly transfused, with iron overload, and
that do not receive chronic iron chelation therapy. As retinal and cerebral microvasculatures
share many morphological and physiological properties, this hypothesis is also confirmed by
previous randomized controlled trials[20], which have demonstrated that regular blood trans-
fusion therapy prevents strokes in children with SCD. However, considering the observational
nature of our study, further interventional studies are necessary to confirm our finding. With
regard to the potentially protective role of HbF, our results are confirmed by a previous study
conducted on 123 children with HbSS.[21] Children with a HbF<15% had higher odds of
developing retinopathy; in addition, children treated with hydroxyurea but with retinopathy
had lower HbF levels compared to children without retinopathy. This suggests that induction
of HbF with hydroxyurea may prevent macular and peripheral ischemia in SCD patients, and
therefore potentially reduce the occurrence of sickle cell maculopathy due to capillary occlu-
sion. A relationship between the presence of retinal thinning and SCD subtype (HbSS and
HbS/β0) was reported in a previous study[8] but not in the present study. This could be
explained by the unequal distribution of sickle cells subtypes and the limited sample size of our
cohort.
Sickle cell maculopathy represents a common finding in SCD patients[6–8], as also con-
firmed by our study where 43% of our SCD population presented with patchy areas of severe
retinal thinning on OCT, consistently present temporally to the macula but sometimes also
involving the temporal quadrant of the macula itself. The prevalence of sickle cell maculopathy
was higher in cases of proliferative retinopathy (62.5%), and when vascular irregularities were
detected in the macula on FA (47%). These results confirm the findings from previous studies.
Mathew et al observed areas of retinal thinning in the temporal macular area in 44% of the
Table 4. Comparison of total retinal thickness of the macular region and of the temporal retina between sickle cell disease eyes and control subjects.
ETDRS grid quadrant Thickness (μm)
SCD subjects (n = 59) Controls (n = 59) p-value
Macula Fovea 267.2 282.7 <0.0001
Inferior 312.3 320.4 0.0014
Nasal 325.8 337.4 <0.0001
Superior 316.6 328.9 <0.0001
Temporal 298.7 312.0 <0.0001
Temporal Retina⇤ Inferior 232.6 240.9 0.0017
Superior 236.3 241.0 0.0114
Temporal 215.8 224.0 0.0006
SCD, sickle cell disease.
⇤Thickness data from the nasal quadrant of the temporally-centered grid were not collected because of overlapping with the temporal quadrant of the fovea-centered
grid
https://doi.org/10.1371/journal.pone.0193582.t004
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SCD eyes, and PSR was more prevalent in these eyes compared with SCD eyes with normal
macular morphology.[8] Brasileiro et al observed focal retinal thinning in 35% of the SCD
patients, with a higher frequency in eyes with proliferative changes.[6] In a study of Ghasemi
Falavarjani et al[9] inner retinal atrophy was detected in 11 eyes (61.1%) and was associated
with a higher ischemic index, which is a parameter previously used to quantify retinal ischemia
in patients with retinal vein occlusion.[22] Overall, these findings suggest that macular ische-
mia and peripheral ischemia are related. Terminal arteriolar branches supply both the tempo-
ral macular area and the retinal periphery, and therefore subclinical ischemia due to vascular
occlusion may easily occur in these areas in patients with SCD; this may explain the association
Table 5. Comparison of individual retinal layer thickness of the macular region and of the temporal retina between sickle cell disease eyes and control subjects.
Retinal layer ETDRS grid quadrant Fovea-centered scan thickness (μm) Temporally-centered scan thickness (μm)
SCD subjects (n = 59) Controls (n = 59) p-value SCD subjects (n = 59) Controls (n = 59) p-value
NFL Inferior 34.070 34.671 0.3859 19.561 19.543 0.9719
Nasal 37.256 36.561 0.2159 n/a n/a n/a
Superior 31.268 31.319 0.9366 18.862 17.888 0.0134
Temporal 18.884 18.163 0.0006 16.126 16.081 0.8901
GCL Inferior 42.234 43.615 0.0316 22.925 23.997 0.0692
Nasal 43.950 46.200 0.0004 n/a n/a n/a
Superior 42.570 45.205 0.0003 21.934 22.014 0.8759
Temporal 39.377 43.387 <0.0001 17.221 17.176 0.9216
IPL Inferior 33.984 35.026 0.0407 21.516 21.846 0.4734
Nasal 35.661 37.161 0.0007 n/a n/a n/a
Superior 34.424 36.102 0.0005 21.858 22.823 0.0795
Temporal 35.653 37.772 0.0009 21.858 22.823 0.0795
INL Inferior 36.457 37.788 0.0316 24.375 26.599 0.0011
Nasal 37.070 38.308 0.0452 n/a n/a n/a
Superior 36.732 37.427 0.2377 24.760 26.180 0.007
Temporal 34.443 36.850 0.0004 21.101 23.235 0.0007
OPL Inferior 29.633 32.590 0.0009 23.260 22.938 0.4468
Nasal 30.619 30.449 0.762 n/a n/a n/a
Superior 33.146 29.485 0.0001 24.486 23.048 <0.0001
Temporal 29.816 30.113 0.7028 21.410 21.401 0.9831
ONL Inferior 56.966 58.135 0.3464 46.056 51.047 <0.0001
Nasal 60.649 67.912 <0.0001 n/a n/a n/a
Superior 57.516 68.829 <0.0001 47.523 53.684 <0.0001
Temporal 60.316 66.655 <0.0001 44.907 49.826 <0.0001
PHOT Inferior 79.362 78.659 0.117 75.271 74.798 0.2325
Nasal 80.722 80.959 0.6303 n/a n/a n/a
Superior 80.870 80.573 0.5748 76.786 75.670 0.0146
Temporal 79.885 79.334 0.2364 74.711 73.729 0.0094
RPE Inferior 15.712 14.034 <0.0001 12.662 11.243 <0.0001
Nasal 16.0470 14.928 <0.0001 n/a n/a n/a
Superior 16.402 14.953 <0.0001 13.246 11.702 <0.0001
Temporal 15.256 13.553 <0.0001 11.907 10.550 <0.0001
SCD, sickle cell disease; NFL, retinal nerve fiber layer; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL,
outer nuclear layer; PHOT, photoreceptor layer; RPE retinal pigment epithelium; n/a = not applicable (thickness data from the nasal quadrant of the temporally-
centered grid were not collected because of overlapping with the temporal quadrant of the fovea-centered grid).
https://doi.org/10.1371/journal.pone.0193582.t005
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Fig 3. Example of individual retinal layer thickness measurement in subject with sickle cell maculopathy, for both
the foveal-centered (“F”) and temporally centered (“T”) scans.Areas of severe thinning are well recognizable as blue
patchy areas on retinal thickness color-coded maps (first row), and correspond to darker areas on the thickness maps
for ganglion cell layer (second row), inner plexiform layer and inner nuclear layer (third row), and outer plexiform
layer (fourth row). The thickness maps for photoreceptors and retinal pigment epithelium do not show any patchy
thinning.
https://doi.org/10.1371/journal.pone.0193582.g003
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between the presence of sickle cell maculopathy and the severity of sickle cell retinopathy. The
predilection of the temporal macula to focal retinal thinning has been described as “retinal
depression sign” by Goldbaum in 1978 [23] This finding may be due to the smaller caliber of
the end arterioles in the temporal macula compared with that in the nasal region[8], or may be
attributable to the fact that temporal macula is a watershed area between the vascular arcades
of the retinal circulation.
To better characterize which specific layers are mostly affected in SCD, we measured the
thickness of each single retinal layer using an automated segmentation software that was previ-
ously validated.[16] To the best of our knowledge, this is the first study that has used single-
layer retinal segmentation of OCT scans in SCD patients. Interestingly, we found a generalized
thinning of the macular and temporal retina in SCD patients compared to matched controls.
Such thinning involved both inner and outer retinal layers (including GCL, IPL, INL, OPL,
and ONL centrally; INL and ONL temporally). Moreover, cases with sickle cell maculopathy
were affected by an even more pronounced thinning temporally to the macula, involving both
inner and outer layers and including the same layers (GCL, IPL, INL, OPL and ONL). Previous
OCT-based studies, conducted without automated segmentation, have shown controversial
results.[6–8] Both studies conducted by Brasileiro et al and Mathew et al demonstrated inner
retinal involvement only.[6, 8] Instead, Hoang et al reported a significant total retinal thinning
in the central macula, but with involvement of the outer retinal layers only.[7] The exact etiol-
ogy of macular thinning in the absence of clinically apparent nonperfusion, however, still
remains unclear. The deep capillary plexus is likely to be the most vulnerable retinal plexus to
an ischemic insult, as it may reside in a watershed region of oxygen supply.[24] Since most of
SCD patients don’t show any acute symptoms, deep retinal plexus ischemia may presumably
reflect a chronic loss of the retinal vascular flow. Furthermore, as in our study the retinal thin-
ning was not limited to the layers supplied by the deep capillary plexus, different levels of
ischemia could explain the more widespread retinal damage. Indeed, ischemic insults may first
involve the deep capillary plexus and consequently further involve the inner retinal circulation.
This hypothesis is confirmed by recent OCT-A studies, showing that nonperfusion or reduced
flow in both superficial and deep capillary plexi may be responsible for macular thinning in
SCD subjects.[10–12]
A new finding of this study is that the retinal thinning involved also the ONL, which
receives oxygen and nutrients from the choriocapillaris. Vaso-occlusive events involving the
Table 6. Comparison of total retinal layer thickness of the macular region and of the temporal retina between sickle cell disease eyes with and without sickle cell
maculopathy.
ETDRS grid quadrant Thickness (μm)
Sickle maculopathy absent (n = 40) Sickle maculopathy present (n = 19) p-value
Macula Fovea 266.5 268.0 0.7514
Inferior 312.4 313.3 0.9097
Nasal 324.6 327.9 0.4390
Superior 315.9 317.7 0.7285
Temporal 299.0 297.5 0.9793
Temporal Retina⇤ Inferior 237.8 224.2 0.0905
Superior 242.2 226.4 0.0130
Temporal 225.2 119.9 <0.0001
⇤Thickness data from the nasal quadrant of the temporally-centered grid were not collected because of overlapping with the temporal quadrant of the fovea-centered
grid
https://doi.org/10.1371/journal.pone.0193582.t006
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choriocapillaris in SCD patients could explain such ONL thinning but we are unable to prove
this due to 3 main reasons. First, the choriocapillaris accounts for the smallest amount of the
choroidal thickness[25], and focal infarctions of the choriocapillaris only may not translate
into a structural change of the overall choroid. Therefore, measuring the choroid by structural
OCT may not be ideal to detect focal infarctions of the choriocapillaris; instead, evaluating the
vascular flow using OCT-A technology might better elucidate the involvement of the chorioca-
pillary vasculature in SCD eyes. Second, we measured the choroidal volume since it provides a












present (n = 19)
p-value Sickle maculopathy absent
(n = 40)
Sickle maculopathy
present (n = 19)
p-value
NFL Inferior 34.445 33.550 0.7421 20.073 18.812 0.5024
Nasal 37.123 37.568 0.7730 n/a n/a n/a
Superior 31.754 30.629 0.5540 19.742 17.627 0.1437
Temporal 18.662 19.267 0.4816 16.815 14.940 0.0655
GCL Inferior 42.525 41.775 0.7549 24.216 20.738 0.0662
Nasal 43.284 45.080 0.4550 n/a n/a n/a
Superior 42.025 43.510 0.4732 23.188 19.943 0.0504
Temporal 40.345 41.765 0.4350 23.332 17.207 0.0020
IPL Inferior 34.128 33.723 0.8285 22.060 20.766 0.3723
Nasal 35.636 35.706 0.9616 n/a n/a n/a
Superior 34.579 34.204 0.7996 22.678 20.368 0.1484
Temporal 35.349 36.074 0.8098 21.371 18.985 0.0170
INL Inferior 35.096 38.711 0.0858 25.433 22.519 0.2247
Nasal 37.014 37.169 0.9234 n/a n/a n/a
Superior 36.181 37.611 0.4174 26.472 21.864 0.0184
Temporal 34.787 33.652 0.6003 23.332 17.207 0.0020
OPL Inferior 30.919 27.479 0.2391 24.285 21.557 0.0406
Nasal 29.760 32.070 0.2588 n/a n/a n/a
Superior 31.490 35.935 0.2120 25.264 23.182 0.1008
Temporal 30.217 29.217 0.6562 23.475 17.904 0.0035
ONL Inferior 55.971 58.601 0.4747 46.672 45.128 0.1988
Nasal 61.566 59.046 0.2327 n/a n/a n/a
Superior 59.429 54.309 0.2024 48.047 46.650 0.2404
Temporal 59.784 61.039 0.6126 46.189 42.804 0.0207
PHOT Inferior 79.126 79.651 0.3798 75.335 75.156 0.7530
Nasal 80.447 81.092 0.4395 n/a n/a n/a
Superior 80.650 81.140 0.5266 76.864 76.723 0.8407
Temporal 79.821 79.941 0.8385 74.794 74.723 0.9277
RPE Inferior 15.821 15.461 0.4413 12.755 12.560 0.6463
Nasal 16.179 15.804 0.5680 n/a n/a n/a
Superior 16.368 16.418 0.9473 13.313 13.215 0.8257
Temporal 15.281 15.201 0.8848 11.845 12.117 0.5798
SCD, sickle cell disease; NFL, retinal nerve fiber layer; GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL,
outer nuclear layer; PHOT, photoreceptor layer; RPE retinal pigment epithelium; n/a = not applicable (thickness data from the nasal quadrant of the temporally-
centered grid were not collected because of overlapping with the temporal quadrant of the fovea-centered grid).
https://doi.org/10.1371/journal.pone.0193582.t007
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more comprehensive assessment of the posterior choroid compared to the single-point thick-
ness measurement strategy.[15] However, measuring the overall volume of the posterior cho-
roid does not allow to detect focal choroidal tissue abnormalities, as instead previously
described by histological studies reporting spontaneous choroidal vascular occlusions and
focal infarctions in patients affected by sickle cell retinopathy.[26, 27] Mathew et al have
recently reported a significantly lower choroidal thickness in SCD patients compared to con-
trols by means of OCT.[8] Third, in this study we were not able to control for the multiple fac-
tors that have been shown to influence the choroidal volume or thickness, such as eye axial
length or time of the OCT scan.[28, 29]
Interestingly, in our study, RPE was consistently found to be thicker in SCD eyes than con-
trols. Although this finding is controversial, it could potentially support the presence of vaso-
occlusive disease of the choriocapillaris in SCD patients. Thus, there is a growing evidence that
RPE hypertrophy is a cardinal feature of the stress response triggered by various perturbations,
such as oxidative damage and iron accumulation. However, only animal studies have been
conducted so far; post mortem histological studies are necessary to confirm the potential
involvement of RPE as a target tissue for oxidative damage in humans.[30, 31]
This study has a number of limitations. First, the sample size was limited; however, it was
sufficient to inform about the primary endpoint of the study as well as to detect meaningful
and consistent differences between SCD patients and controls. Second, despite the exclusion
of patients with previous panphotocoagulation treatment, we included 12 eyes that had previ-
ously undergone focal laser to the periphery. Although unlikely, given that focal laser was
localized only in a small portion of the periphery, vascular findings and macular thickness may
have been affected by laser treatment in this limited number of eyes. Third, further studies
with OCTA are needed to better elucidate the vascular changes in sickle cell maculopathy and
to find a correlation with the thinning of specific retinal layers.
In conclusion, we demonstrated for the first time that chelation therapy likely plays a cru-
cial role in the prevention of sickle cell maculopathy, and HbF may also have a protective role.
The presence of sickle cell maculopathy is associated with more severe forms of sickle cell reti-
nopathy, confirming a potential correlation between macular and peripheral ischemia. Fur-
thermore, a generalized thinning of the macula is present in SCD patients compared to
controls. Thinning involves retinal layers also in eyes without significant signs of macular non-
perfusion on FA, suggesting that subclinical ischemia caused by chronic occlusion may happen
both in the superficial and deep capillary plexi. The outer retina thinning in SCD patients also
suggests that vaso-occlusive ischemic events may occur in the choriocapillaris as well. Because
severe retinal thinning affects visual function and can lead to irreversible visual loss, we suggest
regular ocular checkups for SCD patients.
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